Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd. has announced promising results from its Phase IIb clinical trial for ALS treatment, PrimeC, demonstrating improved survival rates and a 36% slower disease progression. The 12-month trial data indicates that PrimeC effectively regulates iron metabolism, a factor in ALS pathology, leading to better patient outcomes. The company is advancing discussions on the clinical and regulatory future of PrimeC, including potential marketing partnerships.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
